Top Markets
#1 EXOD EXOD +22.08%
#2 Ontology Gas Ontology Gas +14.98%
#3 Status Status +14.56%
#4 Fake World Assets Fake World Assets +11.65%
#5 Derive Derive +11.23%
#6 aelf aelf +10.13%
#7 Gas Gas +6.52%
#8 Anvil Anvil +5.72%
#9 Tornado Cash Tornado Cash +5.44%
#10 The Black Bull The Black Bull +5.21%
Coin of the day
EXOD EXOD
設定
言語
日本
通貨
USD
テーマ
Mendus AB (publ) Mendus AB (publ)

Mendus AB (publ)

IMMU
株式のランク #25837
Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB... Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.
株価
$0.74834668
最終同期: 2026-08-20
時価総額
$45.86M
変化（1日）
-0.15%
変化（1年）
-2.71%
国
SE
取引 Mendus AB (publ) (IMMU)

カテゴリー

Healthcare
Mendus AB (publ)（IMMU）の収益
Aug 2026 時点の収益 TTM: 0
Mendus AB (publ) の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Mendus AB (publ) の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US